A detailed history of Gsa Capital Partners LLP transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 37,884 shares of CTKB stock, worth $244,730. This represents 0.02% of its overall portfolio holdings.

Number of Shares
37,884
Previous 14,647 158.65%
Holding current value
$244,730
Previous $82,000 156.1%
% of portfolio
0.02%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$4.73 - $6.73 $109,911 - $156,385
23,237 Added 158.65%
37,884 $210,000
Q2 2024

Aug 15, 2024

BUY
$5.3 - $6.91 $77,629 - $101,210
14,647 New
14,647 $82,000
Q2 2022

Aug 09, 2022

BUY
$7.41 - $11.56 $546,435 - $852,469
73,743 New
73,743 $791,000

Others Institutions Holding CTKB

About Cytek Biosciences, Inc.


  • Ticker CTKB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 134,627,008
  • Market Cap $870M
  • Description
  • Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...
More about CTKB
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.